Burden of Disease due to Nonalcoholic Fatty Liver Disease
Authors:
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 49 (1) , 1-23
Abstract
No abstract availableKeywords
Funding Information
- Gilead
- Salix
- Tobira
- Bristol Myers
- Shire
- Intercept
- Merck
- AstraZeneca
- Mallinckrodt
- Cumberland
- Novartis
- NIH (RO1 DK 105961)
This publication has 139 references indexed in Scilit:
- Hospital Readmissions Among Patients With Decompensated CirrhosisAmerican Journal of Gastroenterology, 2012
- Upper Limits of Normal for Alanine Aminotransferase Activity in the United States PopulationHepatology, 2011
- An apoptosis panel for nonalcoholic steatohepatitis diagnosisJournal of Hepatology, 2011
- Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver DiseaseJournal of Clinical Gastroenterology, 2011
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §ΔHepatology, 2010
- Quality of life in adults with nonalcoholic fatty liver diseaseHepatology, 2009
- Long-Term Follow-Up of Patients With Nonalcoholic Fatty LiverClinical Gastroenterology and Hepatology, 2009
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- Liver cirrhosisThe Lancet, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005